Nosa Plugs (NOSA) investor relations material

Executive summary

• Net sales for Q1 2026 reached SEK 8,191 thousand, a 94% increase year-over-year, driven by both organic growth and the acquisition of Pharmacure Health Care International AB.

• Gross margin improved sequentially to 63% from 58% in the previous quarter, reflecting margin improvement initiatives, especially for Nozoil.

• EBITDA was SEK -331 thousand, an improvement from SEK -677 thousand in Q1 2025, and in line with internal targets.

• Operating loss widened to SEK -2,032 thousand due to increased amortization from the Pharmacure acquisition, but adjusted operating profit improved year-over-year.

• Cash and cash equivalents stood at SEK 16,768 thousand at quarter-end, supporting ongoing operations and growth initiatives.

Financial highlights

• Net sales: SEK 8,191 thousand (Q1 2025: SEK 4,233 thousand).

• Operating profit: SEK -2,032 thousand (Q1 2025: SEK -1,320 thousand).

• EBITDA: SEK -331 thousand (Q1 2025: SEK -677 thousand).

• Earnings per share: SEK -0.01 (Q1 2025: SEK -0.01).

• Cash flow from operating activities: SEK -95 thousand (Q1 2025: SEK 847 thousand).

• Gross margin: 63% (Q1 2025: 74%).

Outlook and guidance

• Continued focus on expanding European market presence, with recent launches in Austria, France, and Norway.

• Ongoing development and commercialization of the Cerevia (formerly Drug Delivery) platform, with participation in major industry events and pursuit of new partnerships.

• Strengthening of sales and quality assurance teams to support rapid growth.